WO2003062241A8 - Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function - Google Patents
Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor functionInfo
- Publication number
- WO2003062241A8 WO2003062241A8 PCT/US2002/040598 US0240598W WO03062241A8 WO 2003062241 A8 WO2003062241 A8 WO 2003062241A8 US 0240598 W US0240598 W US 0240598W WO 03062241 A8 WO03062241 A8 WO 03062241A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hormone receptor
- succinimidecompounds
- modulators
- analogs
- nuclear hormone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA20040705945A UA78265C2 (en) | 2001-12-19 | 2002-12-18 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
BR0215281-9A BR0215281A (en) | 2001-12-19 | 2002-12-18 | Fused heterocyclic succinimide compounds and their analogues, modulators of nuclear hormone receptor function |
DK02797421T DK1458723T3 (en) | 2001-12-19 | 2002-12-18 | Condensed heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
MXPA04005876A MXPA04005876A (en) | 2001-12-19 | 2002-12-18 | Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function. |
EP02797421A EP1458723B1 (en) | 2001-12-19 | 2002-12-18 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
JP2003562118A JP2005523257A (en) | 2001-12-19 | 2002-12-18 | Fused heterocyclic succinimide compounds and analogs thereof that are modulators of nuclear hormone receptor function |
KR10-2004-7009794A KR20040086248A (en) | 2001-12-19 | 2002-12-18 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
HU0402554A HUP0402554A3 (en) | 2001-12-19 | 2002-12-18 | Condensated heterocyclic succinimide compounds, their use, process for the preparation of some of them and pharmaceutical compositions containing the compounds |
SI200230767T SI1458723T1 (en) | 2001-12-19 | 2002-12-18 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
DE60229435T DE60229435D1 (en) | 2001-12-19 | 2002-12-18 | CONDENSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND THEIR ANALOGUES, MODULATORS OF THE FUNCTION OF NUCLEAR HORMONE RECEPTORS |
CA002471342A CA2471342A1 (en) | 2001-12-19 | 2002-12-18 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
AU2002361785A AU2002361785B2 (en) | 2001-12-19 | 2002-12-18 | Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function |
IL16254702A IL162547A0 (en) | 2001-12-19 | 2002-12-18 | Fused heterocyclic succinimide derivatives and pharmaceutical compositions containing the same |
NZ533471A NZ533471A (en) | 2001-12-19 | 2002-12-18 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
HR20040567A HRP20040567A2 (en) | 2001-12-19 | 2004-06-17 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
IS7324A IS7324A (en) | 2001-12-19 | 2004-06-18 | Synchronous heterocyclic succinimide compounds and their analogues, configured for nuclear hormone receptor activity |
NO20043068A NO20043068L (en) | 2001-12-19 | 2004-07-16 | Condensed heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2511601A | 2001-12-19 | 2001-12-19 | |
US10/025,116 | 2001-12-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003062241A1 WO2003062241A1 (en) | 2003-07-31 |
WO2003062241A8 true WO2003062241A8 (en) | 2004-10-21 |
Family
ID=27609007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/040598 WO2003062241A1 (en) | 2001-12-19 | 2002-12-18 | Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function |
Country Status (31)
Country | Link |
---|---|
EP (1) | EP1458723B1 (en) |
JP (1) | JP2005523257A (en) |
KR (1) | KR20040086248A (en) |
CN (1) | CN1589271A (en) |
AR (1) | AR037950A1 (en) |
AT (1) | ATE411319T1 (en) |
AU (1) | AU2002361785B2 (en) |
BR (1) | BR0215281A (en) |
CA (1) | CA2471342A1 (en) |
CO (1) | CO5640082A2 (en) |
DE (1) | DE60229435D1 (en) |
DK (1) | DK1458723T3 (en) |
ES (1) | ES2314127T3 (en) |
GE (1) | GEP20063817B (en) |
HR (1) | HRP20040567A2 (en) |
HU (1) | HUP0402554A3 (en) |
IL (1) | IL162547A0 (en) |
IS (1) | IS7324A (en) |
MX (1) | MXPA04005876A (en) |
NO (1) | NO20043068L (en) |
NZ (1) | NZ533471A (en) |
PL (1) | PL370904A1 (en) |
PT (1) | PT1458723E (en) |
RU (1) | RU2330038C2 (en) |
SI (1) | SI1458723T1 (en) |
TW (1) | TWI263640B (en) |
UA (1) | UA78265C2 (en) |
UY (1) | UY27595A1 (en) |
WO (1) | WO2003062241A1 (en) |
YU (1) | YU53604A (en) |
ZA (1) | ZA200404812B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7202264B2 (en) | 2003-01-31 | 2007-04-10 | Isis Pharmaceuticals, Inc. | Supports for oligomer synthesis |
FR2860793A1 (en) * | 2003-10-14 | 2005-04-15 | Entomed | New norcantharidin derivatives e.g. used for treating cancer, neurodegenerative diseases, restenosis, diabetes, asthma and bacterial and fungal infections |
DK2708541T3 (en) * | 2003-11-13 | 2015-02-23 | Isis Pharmaceuticals Inc | 5,6-dihydroxy-isoindole derivatives as linkers for oligomeric solid phase synthesis |
US7569689B2 (en) | 2004-01-16 | 2009-08-04 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7605264B2 (en) | 2004-01-16 | 2009-10-20 | Bristol-Myers Squibb Company | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7273881B2 (en) | 2004-01-16 | 2007-09-25 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7253283B2 (en) | 2004-01-16 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7326728B2 (en) | 2004-01-16 | 2008-02-05 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof |
US7625921B2 (en) | 2004-01-16 | 2009-12-01 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
WO2005090300A1 (en) * | 2004-03-17 | 2005-09-29 | Pfizer Products Inc. | Novel benzyl(idene)-lactam derivatives |
US7317024B2 (en) | 2005-01-13 | 2008-01-08 | Bristol-Myers Squibb Co. | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7642273B2 (en) | 2005-01-13 | 2010-01-05 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7411071B2 (en) | 2005-01-13 | 2008-08-12 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7361654B2 (en) | 2005-01-13 | 2008-04-22 | Bristol-Myers Squibb Co. | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
CN101300233A (en) * | 2005-09-09 | 2008-11-05 | 先灵公司 | Azafused cyclin dependent kinase inhibitors |
EP2079466B1 (en) | 2006-09-29 | 2014-01-15 | GlaxoSmithKline LLC | Substituted indole compounds |
WO2008157291A2 (en) * | 2007-06-15 | 2008-12-24 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (3Aα, 4β, 5α, 7β, 7Aα)-4-(OCTAHYDRO-5-ETHYLSULFONAMIDO-4,7-DIMETHYL-1,3-DIOXO-4,7-EPOXY-2H-ISOINDOL-2-YL)-2-(TRIFLUOROMETHYL)BENZONITRILE AND METHOD OF PREPARATION |
KR20120023018A (en) * | 2009-04-30 | 2012-03-12 | 스미또모 가가꾸 가부시키가이샤 | Thiophene derivative |
WO2011007819A1 (en) | 2009-07-17 | 2011-01-20 | 塩野義製薬株式会社 | Pharmaceutical product containing lactam or benzene sulfonamide compound |
CA2773615A1 (en) | 2009-09-11 | 2011-03-17 | Arwed Cleve | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs |
RS58234B1 (en) | 2010-01-14 | 2019-03-29 | Novartis Ag | Use of an adrenal hormone-modifying agent |
WO2014111871A1 (en) | 2013-01-17 | 2014-07-24 | Aurigene Discovery Technologies Limited | 4,5-dihydroisoxazole derivatives as nampt inhibitors |
US9868748B2 (en) | 2013-05-01 | 2018-01-16 | Vitae Pharmaceuticals, Inc. | Thiazolopyrrolidine inhibitors of ROR- γ |
JP6156074B2 (en) * | 2013-11-08 | 2017-07-05 | 住友化学株式会社 | Succinimide compounds and uses thereof |
WO2015116904A1 (en) | 2014-02-03 | 2015-08-06 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ror-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
AU2015364537B2 (en) * | 2014-12-19 | 2020-10-08 | Aragon Pharmaceuticals, Inc. | Process for the preparation of a diarylthiohydantoin compound |
US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
WO2016118666A1 (en) * | 2015-01-20 | 2016-07-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of the androgen receptor |
ES2856931T3 (en) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | ROR-gamma modulators |
RU2018121946A (en) | 2015-11-20 | 2019-12-23 | Вайтаи Фармасьютиклз, Ллк | ROR GAMMA MODULATORS |
TW202220968A (en) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | Modulators of ror-gamma |
ES2922932T3 (en) | 2016-12-29 | 2022-09-21 | Enyo Pharma | Thiophene derivatives as antiviral agents |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | Inhibitors of ror gamma |
MA49685A (en) | 2017-07-24 | 2021-04-14 | Vitae Pharmaceuticals Llc | MMR gamma INHIBITORS |
WO2021189051A1 (en) * | 2020-03-20 | 2021-09-23 | University Of Southern California | Androgen receptor regulation by small molecule enantiomers |
CN114848795B (en) * | 2021-02-03 | 2023-04-14 | 四川大学 | Application of RORa protein and agonist thereof in preparation of anti-aging drugs |
WO2023154939A2 (en) * | 2022-02-14 | 2023-08-17 | The Johns Hopkins University | Gcpii inhibition for the treatment of sarcopenia and aging |
WO2024059200A1 (en) | 2022-09-14 | 2024-03-21 | Halia Therapeutics, Inc. | Nek7 inhibitors |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3320270A (en) * | 1963-10-08 | 1967-05-16 | Tri Kem Corp | Certain 2-acylimidothiazole compounds |
US3215597A (en) * | 1963-10-30 | 1965-11-02 | Dow Chemical Co | Methods and compositions for use in animal husbandry |
US3261845A (en) * | 1964-07-14 | 1966-07-19 | Dow Chemical Co | N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide |
US4892943A (en) * | 1985-10-16 | 1990-01-09 | American Home Products Corporation | Fused bicyclic imides with psychotropic activity |
JPS63170383A (en) * | 1987-02-26 | 1988-07-14 | Nippon Zeon Co Ltd | Alicyclic dicarboximide compound |
WO1991006297A1 (en) * | 1989-10-27 | 1991-05-16 | The Du Pont Merck Pharmaceutical Company | (n-phthalimidoalkyl) piperidines |
CN1103769C (en) * | 1996-10-25 | 2003-03-26 | 第一制药株式会社 | Tricyclic amine derivatives |
FR2764890B1 (en) * | 1997-06-24 | 1999-08-27 | Adir | NOVEL CHROMENIC DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
AU1928800A (en) * | 1998-12-22 | 2000-07-12 | Eli Lilly And Company | Substituted tricyclics |
US20040176324A1 (en) * | 2000-09-19 | 2004-09-09 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
AU2001288213B2 (en) * | 2000-06-28 | 2005-04-14 | Bristol-Myers Squibb Company | Selective androgen receptor modulators and methods for their identification, design and use |
-
2002
- 2002-12-13 TW TW091136163A patent/TWI263640B/en active
- 2002-12-18 DK DK02797421T patent/DK1458723T3/en active
- 2002-12-18 KR KR10-2004-7009794A patent/KR20040086248A/en not_active Application Discontinuation
- 2002-12-18 DE DE60229435T patent/DE60229435D1/en not_active Expired - Fee Related
- 2002-12-18 NZ NZ533471A patent/NZ533471A/en unknown
- 2002-12-18 IL IL16254702A patent/IL162547A0/en unknown
- 2002-12-18 HU HU0402554A patent/HUP0402554A3/en unknown
- 2002-12-18 ES ES02797421T patent/ES2314127T3/en not_active Expired - Lifetime
- 2002-12-18 RU RU2004122403/04A patent/RU2330038C2/en not_active IP Right Cessation
- 2002-12-18 PT PT02797421T patent/PT1458723E/en unknown
- 2002-12-18 JP JP2003562118A patent/JP2005523257A/en not_active Withdrawn
- 2002-12-18 CA CA002471342A patent/CA2471342A1/en not_active Abandoned
- 2002-12-18 GE GE5693A patent/GEP20063817B/en unknown
- 2002-12-18 AT AT02797421T patent/ATE411319T1/en not_active IP Right Cessation
- 2002-12-18 SI SI200230767T patent/SI1458723T1/en unknown
- 2002-12-18 PL PL02370904A patent/PL370904A1/en not_active Application Discontinuation
- 2002-12-18 WO PCT/US2002/040598 patent/WO2003062241A1/en active Application Filing
- 2002-12-18 BR BR0215281-9A patent/BR0215281A/en not_active IP Right Cessation
- 2002-12-18 AU AU2002361785A patent/AU2002361785B2/en not_active Ceased
- 2002-12-18 MX MXPA04005876A patent/MXPA04005876A/en active IP Right Grant
- 2002-12-18 EP EP02797421A patent/EP1458723B1/en not_active Expired - Lifetime
- 2002-12-18 YU YU53604A patent/YU53604A/en unknown
- 2002-12-18 UA UA20040705945A patent/UA78265C2/en unknown
- 2002-12-18 CN CNA028281063A patent/CN1589271A/en active Pending
- 2002-12-19 AR ARP020105038A patent/AR037950A1/en unknown
- 2002-12-19 UY UY27595A patent/UY27595A1/en not_active Application Discontinuation
-
2004
- 2004-06-16 CO CO04056353A patent/CO5640082A2/en not_active Application Discontinuation
- 2004-06-17 HR HR20040567A patent/HRP20040567A2/en not_active Application Discontinuation
- 2004-06-17 ZA ZA200404812A patent/ZA200404812B/en unknown
- 2004-06-18 IS IS7324A patent/IS7324A/en unknown
- 2004-07-16 NO NO20043068A patent/NO20043068L/en not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003062241A8 (en) | Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function | |
WO2003053358A3 (en) | Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function | |
WO2003053354A3 (en) | Fused cyclic modulators of nuclear hormone receptor function | |
MY138531A (en) | Fused heterocyclic succinmide compounds and analogs thereof, modulators of nuclear hormone receptor function | |
WO2002000653A3 (en) | Fused cyclic compounds as modulators of nuclear hormone receptor function | |
WO2006002102A3 (en) | Spirocyclic compounds useful as modulators of nuclear hormone receptor function | |
WO2002024909A3 (en) | Receptor nucleic acids and polypeptides | |
IL219397A0 (en) | Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same | |
HUP0304055A2 (en) | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | |
WO2000066590A3 (en) | Tetracyclic progesterone receptor modulator compounds and methods | |
HUP0402264A3 (en) | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines process for preparing them, pharmaceutical compositions containing them and use thereof | |
WO2005048935A3 (en) | Methods of modulating immunity | |
CA2412161A1 (en) | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | |
IL162185A0 (en) | Phenylpropionate derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same | |
WO2004093800A3 (en) | Thyronamine derivatives and analogs and methods of use thereof | |
IL140140A0 (en) | Thyroid hormone analogues and methods for their preparation | |
HUP0401350A3 (en) | Novel imidazopyridine compounds with therapeutic effect, process for their preparation and pharmaceutical compositions containing them | |
PL366565A1 (en) | Fused cyclic modulators of nuclear hormone receptor function | |
EP1854798A3 (en) | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | |
PL373192A1 (en) | Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them | |
MXPA02012015A (en) | Ligands of integrin receptors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-536/04 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 533471 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1687/DELNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 162547 Country of ref document: IL Ref document number: PA/a/2004/005876 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002797421 Country of ref document: EP Ref document number: 2004/04812 Country of ref document: ZA Ref document number: P20040567A Country of ref document: HR Ref document number: 200404812 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002361785 Country of ref document: AU Ref document number: 2471342 Country of ref document: CA Ref document number: 2003562118 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047009794 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref country code: GE Ref document number: GE P |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8309 Country of ref document: GE Ref document number: 1200400669 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004122403 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028281063 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002797421 Country of ref document: EP |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 31/2003 UNDER (71) REPLACE "BRISTOLS-MYERS SQUIBB COMPANY" BY "BRISTOL-MYERS SQUIBB COMPANY"; UNDER (72, 75) REPLACE "PICKERING, DARCIA, A." BY "PICKERING, DACIA, A." |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2004-500877 Country of ref document: PH |